YMTracker DRIPCalc v2 Launch sale

NEW Our free Dividend Tracker is live — see what your stocks pay you

Add your stocks and see every dividend they pay you — dates, amounts, and reinvested shares.

JANX | NASDAQ

$18.35 -$0.04 | -0.22%

TREND SIGNAL: Signal available — unlock to view

Signal available — unlock to view

|2026-10-09

Add to favoritesFavorite

Company Overview:

Market Cap: $1.12B

Trailing PE: N/A

FWD PE: —

Payout Ratio (TTM): —

52-Week Range: $12.12 - $35.34

5.3 Year JANX Performance Metrics:

Total Return (with DRIP): -27.0% (-5.77% CAGR)

Total Return (no DRIP): -27.0% (-5.77% CAGR)

Share Price: -27.0% (-5.77% CAGR)

Yield on Cost (with DRIP): —

Total Invested: $10,000

Total Value (with DRIP): $7,296

Total Return $ (with DRIP): -$2,704

JANX Total Return

1M 3M 6M YTD 1Y 3Y 5Y 10Y

JANX Price Chart

1M 3M 6M YTD 1Y 3Y 5Y 10Y All

Unlock All Reports & Research Dividend Stocks like a BOSS!

Get 3 Months Free with Annual Plan

PRO

$171 ($14.25/mo) $102.60/yr ($8.55/mo)

7-day free trial

Unlimited Portfolio Tracker
Portfolio - Lots/Sales/Dividends
Portfolio Auto-DRIP
Buy/Sell Signals Dashboard
Stock Fundamentals
Compare Stocks Side-by-Side
Revenue & EPS Estimates
DCF Valuation Modeling

Try it free for 7 days

Combined 55% Lifetime Discount

Most Popular

PREMIUM

$288 ($24/mo) $172.80/yr ($14.40/mo)

7-day free trial

Everything in Pro
YieldMax PNL Tracker
YieldMax NAV Erosion Alerts
YM ETFs Trend Signals
9/21 EMA Trend Signals
Stocks Dashboard

Try it free for 7 days

Combined 55% Lifetime Discount

ULTRA

$576 ($48/mo) $345.60/yr ($28.80/mo)

7-day free trial

Everything in Premium
15min & 1hr Intraday Signals
Group & weekly ETF estimates
YouTuber Mode
Trades summary + CSV export
Priority data & support

Try it free for 7 days

Combined 55% Lifetime Discount

JANX Financials: Earnings, Revenue, Cash Flow, Ebitda, Cash/Debt, Shares Float, etc:

JANX - Revenue

JANX Revenue CAGR:1Y: 0.00%2Y: 7.42%5Y: 84.37%10Y: 0.00%

JANX - Earnings Per Share (EPS)

JANX EPS CAGR:1Y: 0.00%2Y: 0.00%5Y: 0.00%10Y: 0.00%

JANX - Net Income

🔓 See the full chart40% off right now · 7-day free trial

JANX Net Income CAGR:1Y: 0.00%2Y: 0.00%5Y: 0.00%10Y: 0.00%

JANX - EBITDA

🔓 See the full chart40% off right now · 7-day free trial

JANX EBITDA CAGR:1Y: 0.00%2Y: 0.00%5Y: 0.00%10Y: 0.00%

JANX - Free Cash Flow

🔓 See the full chart40% off right now · 7-day free trial

JANX Free Cash Flow CAGR:1Y: 0.00%2Y: 0.00%5Y: 0.00%10Y: 0.00%

JANX - Free Cash Flow / Share

🔓 See the full chart40% off right now · 7-day free trial

JANX Free Cash Flow / Share CAGR:1Y: 0.00%2Y: 0.00%5Y: 0.00%10Y: 0.00%

JANX - Operating Income

🔓 See the full chart40% off right now · 7-day free trial

JANX Operating Income CAGR:1Y: 0.00%2Y: 0.00%5Y: 0.00%10Y: 0.00%

JANX - Gross Profit

🔓 See the full chart40% off right now · 7-day free trial

JANX Gross Profit CAGR:1Y: 0.00%2Y: 10.62%5Y: 0.00%10Y: 0.00%

JANX - Shares Outstanding

🔓 See the full chart40% off right now · 7-day free trial

JANX Shares Outstanding CAGR:1Y: 1.67%2Y: 7.51%5Y: 44.38%10Y: 0.00%

JANX - Share Buybacks

🔓 See the full chart40% off right now · 7-day free trial

JANX Share Buybacks CAGR:1Y: 0.00%2Y: 0.00%5Y: 0.00%10Y: 0.00%

JANX - Stock-Based Comp

🔓 See the full chart40% off right now · 7-day free trial

JANX Stock-Based Comp CAGR:1Y: -17.32%2Y: 25.46%5Y: 47.98%10Y: 0.00%

JANX - Expenses

🔓 See the full chart40% off right now · 7-day free trial

JANX Expenses CAGR:1Y: 0.42%2Y: 123.61%5Y: 43.16%10Y: 0.00%

JANX - Revenue vs Net Income

🔓 See the full chart40% off right now · 7-day free trial

JANX - EPS vs FCF / Share

🔓 See the full chart40% off right now · 7-day free trial

JANX - EPS vs PE Ratio

🔓 See the full chart40% off right now · 7-day free trial

JANX - FCF vs FCF / Share

🔓 See the full chart40% off right now · 7-day free trial

JANX - FCF vs Stock Based Comp

🔓 See the full chart40% off right now · 7-day free trial

JANX - Cash & Debt

🔓 See the full chart40% off right now · 7-day free trial

Revenue, EPS, Net Income & Ebitda - Estimates VS Actual:

JANX - REVENUE: Actual + Estimates

🔓 See the full chart40% off right now · 7-day free trial

JANX Actual Revenue CAGR:1Y: 0.00%2Y: 7.42%5Y: 84.37%10Y: 0.00%

JANX - EPS: Actual + Estimates

🔓 See the full chart40% off right now · 7-day free trial

JANX Actual EPS CAGR:1Y: 0.00%2Y: 0.00%5Y: 0.00%10Y: 0.00%

JANX - NET INCOME: Actual + Estimates

🔓 See the full chart40% off right now · 7-day free trial

JANX Actual Net Income CAGR:1Y: 0.00%2Y: 0.00%5Y: 0.00%10Y: 0.00%

JANX - EBITDA: Actual + Estimates

🔓 See the full chart40% off right now · 7-day free trial

JANX Actual EBITDA CAGR:1Y: 0.00%2Y: 0.00%5Y: 0.00%10Y: 0.00%

Ratios, Profit Margins & Return on Capital:

JANX - Net Profit Margin

🔓 See the full chart40% off right now · 7-day free trial

JANX Net Profit Margin CAGR:1Y: 0.00%2Y: 0.00%5Y: 0.00%10Y: 0.00%

JANX - Gross Profit Margin

🔓 See the full chart40% off right now · 7-day free trial

JANX Gross Profit Margin CAGR:1Y: 0.00%2Y: 2.97%5Y: 0.00%10Y: 0.00%

JANX - Price to Earnings

🔓 See the full chart40% off right now · 7-day free trial

JANX Price to Earnings CAGR:1Y: 0.00%2Y: 0.00%5Y: 0.00%10Y: 0.00%

JANX - Price To Sales Ratio

🔓 See the full chart40% off right now · 7-day free trial

JANX Price To Sales Ratio CAGR:1Y: 0.00%2Y: -39.27%5Y: -28.93%10Y: 0.00%

JANX - Return on Capital Employed

🔓 See the full chart40% off right now · 7-day free trial

JANX Return on Capital Employed CAGR:1Y: 0.00%2Y: 0.00%5Y: 0.00%10Y: 0.00%

JANX - Return on Invested Capital

🔓 See the full chart40% off right now · 7-day free trial

JANX Return on Invested Capital CAGR:1Y: 0.00%2Y: 0.00%5Y: 0.00%10Y: 0.00%

Projected Future Returns & Dividends for JANX

Based on past 5.3-year performance, here are JANX growth metrics:

Share price CAGR of -5.77%
Dividend CAGR of +0%

Using JANX CAGR metrics, we can estimate that your initial $10000 investment, over the next 10 years, should grow as follows:

	JANX (DRIP)	JANX - No DRIP
Current Price	$18.35	$18.35
Start Shares	544.96	544.96
Start Value	$10,000	$10,000

After 10 years:
Final Share Count	544.96	544.96
Dividends Payment	$0.00	$0.00
Annual Dividends	$0	$0
Yield on cost	0.00%	0.00%
Share Price	$10.12	$18.35
Total Dividends	$0	$0
Final Value	$5,517	$10,000

Estimated Future Value + Dividends - JANX

NOTE: Above numbers are our estimate based on JANX's Dividend and Price CAGR over past 5.3 years. These numbers should only be considered as "potential future returns"! DRIP assumes reinvesting dividends; No-DRIP assumes collecting dividends as cash.

We cannot guarantee that your actual returns will meet these estimates.

Get the best Dividend Stock Research Tools:

Get 3 Months Free with Annual Plan

PRO

$171 ($14.25/mo) $102.60/yr ($8.55/mo)

7-day free trial

Unlimited Portfolio Tracker
Portfolio - Lots/Sales/Dividends
Portfolio Auto-DRIP
Buy/Sell Signals Dashboard
Stock Fundamentals
Compare Stocks Side-by-Side
Revenue & EPS Estimates
DCF Valuation Modeling

Try it free for 7 days

Combined 55% Lifetime Discount

Most Popular

PREMIUM

$288 ($24/mo) $172.80/yr ($14.40/mo)

7-day free trial

Everything in Pro
YieldMax PNL Tracker
YieldMax NAV Erosion Alerts
YM ETFs Trend Signals
9/21 EMA Trend Signals
Stocks Dashboard

Try it free for 7 days

Combined 55% Lifetime Discount

ULTRA

$576 ($48/mo) $345.60/yr ($28.80/mo)

7-day free trial

Everything in Premium
15min & 1hr Intraday Signals
Group & weekly ETF estimates
YouTuber Mode
Trades summary + CSV export
Priority data & support

Try it free for 7 days

Combined 55% Lifetime Discount

Company Info

Janux Therapeutics, Inc. (JANX) had its IPO on 2021-06-11, and is traded on NASDAQ stock exchange.

Janux Therapeutics, Inc. is a biopharmaceutical company dedicated to developing innovative cancer therapies. The firm leverages its proprietary Tumor Activated T Cell Engager (TRACTr) platform technology to create treatments designed to activate the body's T cells to fight tumors. Currently, Janux has several promising TRACTr product candidates in their early preclinical or discovery stages, which are engineered to target specific antigens such as prostate-specific membrane antigen, epidermal growth factor receptor, and trophoblast cell surface antigen 2. In addition to its TRACTr pipeline, the company is also developing a Tumor Activated Immunomodulator (TRACIr) — a costimulatory bispecific candidate designed to enhance T cell anti-tumor activity by engaging with programmed death-ligand 1 and CD28. Furthermore, a specific focus for their EGFR-TRACTr program is addressing epidermal growth factor receptor, a target prevalent in many cancer types and already a focus of numerous approved monoclonal antibody treatments. Janux Therapeutics, Inc. was founded in 2017 and is headquartered in La Jolla, California.

JANX website: https://www.januxrx.com

Get Full Access to All Reports with DRIPCalc PRO

Get 3 Months Free with Annual Plan

PRO

$171 ($14.25/mo) $102.60/yr ($8.55/mo)

7-day free trial

Unlimited Portfolio Tracker
Portfolio - Lots/Sales/Dividends
Portfolio Auto-DRIP
Buy/Sell Signals Dashboard
Stock Fundamentals
Compare Stocks Side-by-Side
Revenue & EPS Estimates
DCF Valuation Modeling

Try it free for 7 days

Combined 55% Lifetime Discount

Most Popular

PREMIUM

$288 ($24/mo) $172.80/yr ($14.40/mo)

7-day free trial

Everything in Pro
YieldMax PNL Tracker
YieldMax NAV Erosion Alerts
YM ETFs Trend Signals
9/21 EMA Trend Signals
Stocks Dashboard

Try it free for 7 days

Combined 55% Lifetime Discount

ULTRA

$576 ($48/mo) $345.60/yr ($28.80/mo)

7-day free trial

Everything in Premium
15min & 1hr Intraday Signals
Group & weekly ETF estimates
YouTuber Mode
Trades summary + CSV export
Priority data & support

Try it free for 7 days

Combined 55% Lifetime Discount

Loading signals…

DCF Model — JANX

Value from:

EPS (TTM)icompany profit per share over the last 12 months

EPS Growth %ihow fast profit per share grows each of the next 5 years — prefilled with what analysts expect

EPS growth after year 5 (forever)ithe slower pace once the fast 5 years are over — only drives years 6-10 of the price path below

Exit multiple (PE in 5 yrs)iwhat buyers pay per $1 of profit in 2031 — prefilled with today’s forward PE

Desired return %/yrithe yearly return you want from buying today — the S&P has done ~14%/yr, ask for more from a single stock

FCF growth %/yr (next 5 yrs)ihow fast free cash flow grows while the company is still expanding fast

Years of fast FCF growthihow many years the fast growth lasts before the business settles down

FCF growth after year 5 (forever)ithe slow, steady pace once the company is mature — usually 2-3%, near inflation. Must stay below your target return

Risk-free rate %iwhat a 10-yr US treasury pays with zero risk — the floor any risky stock must beat

Your target return %/yrithe yearly return you want for taking this risk — rule of thumb: risk-free rate + extra for risk

FCF base ($M, TTM)ilast 12 months of free cash flow, added up from reported quarters

Include dividends in returnidividends hand you part of the return in cash, so the share price needs to climb less

Pay up to today

—

vs current price $18.35

—

Cash flow & implied price by year

FCF is negative or missing for this company (common for banks) — the model discounts EPS instead.

EPS is negative or missing for this company — Simple mode uses free cash flow per share instead.

Free cash flow today

—

grows for the next years

Then mature

—

every future dollar counted back to today

Pile of today-dollars

—

÷ shares

Implied price path

Year	FCF	Implied price

Sensitivity — fair value: growth ↓ × target return →

× Free Portfolio Tracker

Own JANX? See every dividend it's paid you

Add your JANX shares to a free account and every payment you've received is listed — dated, in dollars — with reinvested shares counted and monthly totals. Room for 4 more stocks.

✓Every JANX dividend you've received, dated, with the amount
✓Reinvested (DRIP) shares counted for you
✓Monthly totals across up to 5 stocks

See my JANX payments →

Free plan · up to 5 holdings